Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,456 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin-based or irinotecan-based therapy for colorectal cancer.
Takahashi S, Sakamoto Y, Denda T, Takashima A, Komatsu Y, Nakamura M, Ohori H, Yamaguchi T, Kobayashi Y, Baba H, Kotake M, Amagai K, Kondo H, Shimada K, Sato A, Yuki S, Okita A, Ouchi K, Komine K, Watanabe M, Morita S, Ishioka C. Takahashi S, et al. Among authors: sakamoto y. Cancer Sci. 2021 Apr;112(4):1567-1578. doi: 10.1111/cas.14841. Epub 2021 Feb 27. Cancer Sci. 2021. PMID: 33548159 Free PMC article. Clinical Trial.
Overexpression of DRAM enhances p53-dependent apoptosis.
Takahashi M, Kakudo Y, Takahashi S, Sakamoto Y, Kato S, Ishioka C. Takahashi M, et al. Among authors: sakamoto y. Cancer Med. 2013 Feb;2(1):1-10. doi: 10.1002/cam4.39. Epub 2013 Feb 3. Cancer Med. 2013. PMID: 24133622 Free PMC article.
Intermittent Withdrawal of Oxaliplatin for Alleviating Neurotoxicity during Oxaliplatin-Based Chemotherapy for Japanese Patients with Inoperable or Metastatic Colorectal Cancer: A Phase 2 Multicenter Study.
Kato S, Imai H, Gamoh M, Takahata T, Ohori H, Yasuda K, Niitani T, Murakawa Y, Amagai K, Isobe H, Shindo Y, Kuroki M, Sakamoto Y, Shimodaira H, Yoshioka T, Ishioka C. Kato S, et al. Among authors: sakamoto y. Tohoku J Exp Med. 2018 May;245(1):21-28. doi: 10.1620/tjem.245.21. Tohoku J Exp Med. 2018. PMID: 29743448 Free article. Clinical Trial.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, Saito K, Kawaguchi Y, Kamio T, Kojima A, Sugihara M, Yamaguchi K; DESTINY-Gastric01 Investigators. Shitara K, et al. N Engl J Med. 2020 Jun 18;382(25):2419-2430. doi: 10.1056/NEJMoa2004413. Epub 2020 May 29. N Engl J Med. 2020. PMID: 32469182 Clinical Trial.
Phase II study of trifluridine/tipiracil (TAS-102) therapy in elderly patients with colorectal cancer (T-CORE1401): geriatric assessment tools and plasma drug concentrations as possible predictive biomarkers.
Takahashi M, Sakamoto Y, Ohori H, Tsuji Y, Kuroki M, Kato S, Otsuka K, Komine K, Takahashi M, Takahashi S, Shirota H, Ouchi K, Takahashi Y, Imai H, Shibata H, Yoshioka T, Tanaka M, Yamaguchi H, Yamaguchi T, Shimodaira H, Ishioka C. Takahashi M, et al. Among authors: sakamoto y. Cancer Chemother Pharmacol. 2021 Sep;88(3):393-402. doi: 10.1007/s00280-021-04277-3. Epub 2021 May 24. Cancer Chemother Pharmacol. 2021. PMID: 34028598 Free PMC article. Clinical Trial.
Phase II Study of the Reuse of Trastuzumab with Docetaxel beyond Progression after First-Line Treatment in Second-Line Treatment for Unresectable, Metastatic Gastric Cancer (T-CORE1203).
Takahashi M, Sakamoto Y, Otsuka K, Kanbe M, Ohori H, Shindo Y, Honda H, Saijo K, Ouchi K, Murakawa Y, Takahashi H, Kawai S, Tanaka Y, Yamaguchi T, Shimodaira H, Yoshioka T, Ishioka C. Takahashi M, et al. Among authors: sakamoto y. Tohoku J Exp Med. 2021 May;254(1):49-55. doi: 10.1620/tjem.254.49. Tohoku J Exp Med. 2021. PMID: 34053967 Free article. Clinical Trial.
3,456 results